<span item_type="fundamental" item_id="26317fec24aab6a86d4eb3e2ddba0c4b" counter_id="ST/US/REVBW" env="prod"></span><span item_type="announcement" item_id="579903437488982529" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -1.77.</p><p></p><h3>Operational Metrics</h3><ul><li>Net loss for the three months ended September 30, 2025: $1.9 million, or - $1.77 basic and diluted net loss per share, compared to a net loss of $2.2 million, or - $40.15 basic and diluted net loss per share for the same period in 2024.</li><li>Net loss for the nine months ended September 30, 2025: $6.4 million, or - $9.76 basic and diluted net loss per share, compared to a net loss of $13.3 million, or - $354.05 basic and diluted net loss per share for the same period in 2024.</li><li>Research and development expenses for the three months ended September 30, 2025: $922,857, compared to $830,981 for the same period in 2024.</li><li>Research and development expenses for the nine months ended September 30, 2025: $3,099,667, compared to $2,943,492 for the same period in 2024.</li><li>General and administrative expenses for the three months ended September 30, 2025: $1,020,154, compared to $965,705 for the same period in 2024.</li><li>General and administrative expenses for the nine months ended September 30, 2025: $3,399,559, compared to $3,277,729 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000119312525269696/revb-ex99_1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash and cash equivalents as of September 30, 2025: $12.7 million, compared to $6.5 million as of December 31, 2024.</li><li>Net cash used for operating activities for the nine months ended September 30, 2025: $6.3 million, compared to $14.6 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000119312525269696/revb-ex99_1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Received gross proceeds of $9.6 million from warrant inducement in September 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000119312525269696/revb-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Revelation believes that its current cash and cash equivalents are sufficient to fund operations through the third quarter of 2026.</li><li>The company looks forward to meeting with the FDA later this year to gain agreement on the clinical development path to registration of Gemini.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1810560/000119312525269696/revb-ex99_1.htm"></span></li></ul>

Revelation Biosciences - CW27 | 8-K: FY2025 Q3 Revenue: USD 0